<!DOCTYPE html>
<html>
  <head>
    <title>NSCLC Results</title>
    <meta charset="UTF-8">
    <meta name="description" content="Lung risk result">
    <meta name="author" content="Xavier Orcutt">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    <link rel="stylesheet" type="text/css" href="../../static/css/mystyle.css"> 
    <script src="../../static/scripts/myscripts.js"></script>
  </head>
  
  <body>
    
    <!-- Header -->
    <header>
        <h1>NSCLC Results</h1>
    </header>
    
    <!-- ESTIMATED INDIVIDUAL SURVIVAL -->
    <p>This patient's estimated median overall survival: <span class="med_surv_estimate"> {{ med_surv_est }} days </span></p>

    <p>Real-world survival estimates for therapies that could be relevant to this patient based on their biomarker status can be found below.</p>
  
    <!-- EGFR POSITIVE -->
    {% if bio_status == "egfr_positive" %}
    <div class="section-box">
      <p class="treatment"> Osimertinib or standard EGFR-TKI</p>

      <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ flaura_risk }} </p>
      
      {% if flaura_risk == "Low" %}
      <p><span class="risk-benefit">Based on the patient's risk, is osimertinib expected to offer a survival advantage over standard EGFR-TKI?</span> Yes</p>

      <p>Click below for more information on progression free survival (PFS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1713137">FLAURA</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">PFS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/flaura_low.png">
        </div>
      </div>

      {% elif flaura_risk == "Medium" %}
      <p><span class="risk-benefit">Based on the patient's risk, is osimertinib expected to offer a survival advantage over standard EGFR-TKI?</span> Yes</p>

      <p>Click below for more information on progression free survival (PFS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1713137">FLAURA</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">PFS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/flaura_med.png">
        </div>
      </div>
       
      {% elif flaura_risk == "High"%}
      <p><span class="risk-benefit">Based on the patient's risk, is osimertinib expected to offer a survival advantage over standard EGFR-TKI?</span> No</p>

      <p>Click below for more information on progression free survival (PFS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1713137">FLAURA</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">PFS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/flaura_high.png">
        </div>
      </div>
      {% endif %}

      <div class="collapsible">
        <button class="collapsible-button">RCT comparison</button>
        <div class="content">
          <img src="../../static/images/lung/flaura_summary.png">
        </div>
      </div>
    </div>
    {% endif %}

    <!-- LOW PDL1 -->
    {% if bio_status == 'pdl1_low' %}

    <!-- LOW PDL1: KEYNOTE-189 -->
    <div class="section-box">
      <p class="treatment"> Pembrolizumab plus chemotherapy or chemotherapy</p>

      <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ key189_risk }} </p>
      
      {% if key189_risk == "Low" %}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab plus chemotherapy expected to offer a survival advantage over chemotherapy alone?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1801005">KEYNOTE-189</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key189_low.png">
        </div>
      </div>

      {% elif key189_risk == "Medium" %}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab plus chemotherapy expected to offer a survival advantage over chemotherapy alone?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1801005">KEYNOTE-189</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key189_med.png">
        </div>
      </div>
       
      {% elif key189_risk == "High"%}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab plus chemotherapy expected to offer a survival advantage over chemotherapy alone?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1801005">KEYNOTE-189</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key189_high.png">
        </div>
      </div>
      {% endif %}

      <div class="collapsible">
        <button class="collapsible-button">RCT comparison</button>
        <div class="content">
          <img src="../../static/images/lung/key189_summary.png">
        </div>
      </div>
    </div>

    <div class="space-result"></div>

    <!-- LOW PDL1: KEYNOTE-042 -->
    <div class="section-box">
      <p class="treatment"> Pembrolizumab or chemotherapy in low PDL1</p>

      <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ key042_risk }} </p>

      {% if key042_risk == "Low" %}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab expected to offer a survival advantage over chemotherapy?</span> No</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext">KEYNOTE-042</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key042_low.png">
        </div>
      </div>

      {% elif key042_risk == "Medium" %}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab expected to offer a survival advantage over chemotherapy?</span> No</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext">KEYNOTE-042</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key042_med.png">
        </div>
      </div>
       
      {% elif key042_risk == "High"%}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab expected to offer a survival advantage over chemotherapy?</span> No</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext">KEYNOTE-042</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key042_high.png">
        </div>
      </div>
      {% endif %}

      <div class="collapsible">
        <button class="collapsible-button">RCT comparison</button>
        <div class="content">
          <img src="../../static/images/lung/key042_summary.png">
        </div>
      </div>
    </div>

    <div class="space-result"></div>

    <!-- LOW PDL1: CHECKMATE-078 -->
    <div class="section-box">
      <p class="treatment"> Second-line nivolumab or docetaxel </p>

      <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ check_risk }} </p>

      {% if check_risk == "Low" %}
      <p><span class="risk-benefit">Based on the patient's risk, is second-line nivolumab expected to offer a survival advantage over docetaxel?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://pubmed.ncbi.nlm.nih.gov/30659987/">CHECKMATE-078</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/check_low.png">
        </div>
      </div>

      {% elif check_risk == "Medium" %}
      <p><span class="risk-benefit">Based on the patient's risk, is second-line nivolumab expected to offer a survival advantage over docetaxel?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://pubmed.ncbi.nlm.nih.gov/30659987/">CHECKMATE-078</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/check_med.png">
        </div>
      </div>
       
      {% elif check_risk == "High"%}
      <p><span class="risk-benefit">Based on the patient's risk, is second-line nivolumab expected to offer a survival advantage over docetaxel?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://pubmed.ncbi.nlm.nih.gov/30659987/">CHECKMATE-078</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/check_high.png">
        </div>
      </div>
      {% endif %}

      <div class="collapsible">
        <button class="collapsible-button">RCT comparison</button>
        <div class="content">
          <img src="../../static/images/lung/check_summary.png">
        </div>
      </div>
    </div>
    {% endif %}

    <!-- HIGH PDL1 -->
    {% if bio_status == 'pdl1_high' %}

    <!-- HIGH PDL1: KEYNOTE-189 -->
    <div class="section-box">
      <p class="treatment"> Pembrolizumab plus chemotherapy or chemotherapy</p>

      <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ key189_risk }} </p>
      
      {% if key189_risk == "Low" %}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab plus chemotherapy expected to offer a survival advantage over chemotherapy alone?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1801005">KEYNOTE-189</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key189_low.png">
        </div>
      </div>

      {% elif key189_risk == "Medium" %}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab plus chemotherapy expected to offer a survival advantage over chemotherapy alone?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1801005">KEYNOTE-189</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key189_med.png">
        </div>
      </div>
       
      {% elif key189_risk == "High"%}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab plus chemotherapy expected to offer a survival advantage over chemotherapy alone?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1801005">KEYNOTE-189</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key189_high.png">
        </div>
      </div>
      {% endif %}

      <div class="collapsible">
        <button class="collapsible-button">RCT comparison</button>
        <div class="content">
          <img src="../../static/images/lung/key189_summary.png">
        </div>
      </div>
    </div>

    <div class="space-result"></div>

    <!-- HIGH PDL1: KEYNOTE-024 -->
    <div class="section-box">
      <p class="treatment"> Pembrolizumab or chemotherapy in high PDL1</p>

      <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ key024_risk }} </p>

      {% if key024_risk == "Low" %}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab expected to offer a survival advantage over chemotherapy?</span> No</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1606774">KEYNOTE-024</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key024_low.png">
        </div>
      </div>

      {% elif key024_risk == "Medium" %}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab expected to offer a survival advantage over chemotherapy?</span> No</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1606774">KEYNOTE-024</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key024_med.png">
        </div>
      </div>
       
      {% elif key024_risk == "High"%}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab expected to offer a survival advantage over chemotherapy?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1606774">KEYNOTE-024</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key024_high.png">
        </div>
      </div>
      {% endif %}

      <div class="collapsible">
        <button class="collapsible-button">RCT comparison</button>
        <div class="content">
          <img src="../../static/images/lung/key024_summary.png">
        </div>
      </div>
    </div>

    <div class="space-result"></div>

    <!-- HIGH PDL1: CHECKMATE-078 -->
    <div class="section-box">
      <p class="treatment"> Second-line nivolumab or docetaxel </p>

      <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ check_risk }} </p>

      {% if check_risk == "Low" %}
      <p><span class="risk-benefit">Based on the patient's risk, is second-line nivolumab expected to offer a survival advantage over docetaxel?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://pubmed.ncbi.nlm.nih.gov/30659987/">CHECKMATE-078</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/check_low.png">
        </div>
      </div>

      {% elif check_risk == "Medium" %}
      <p><span class="risk-benefit">Based on the patient's risk, is second-line nivolumab expected to offer a survival advantage over docetaxel?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://pubmed.ncbi.nlm.nih.gov/30659987/">CHECKMATE-078</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/check_med.png">
        </div>
      </div>
       
      {% elif check_risk == "High"%}
      <p><span class="risk-benefit">Based on the patient's risk, is second-line nivolumab expected to offer a survival advantage over docetaxel?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://pubmed.ncbi.nlm.nih.gov/30659987/">CHECKMATE-078</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/check_high.png">
        </div>
      </div>
      {% endif %}

      <div class="collapsible">
        <button class="collapsible-button">RCT comparison</button>
        <div class="content">
          <img src="../../static/images/lung/check_summary.png">
        </div>
      </div>
    </div>
    {% endif %}

    <!-- ZERO OR UNKNOWN PDL1 -->
    {% if bio_status == 'pdl1_zna' %}

    <!-- ZERO OR UNKNOWN PDL1: KEYNOTE-189 -->
    <div class="section-box">
      <p class="treatment"> Pembrolizumab plus chemotherapy or chemotherapy</p>

      <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ key189_risk }} </p>
      
      {% if key189_risk == "Low" %}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab plus chemotherapy expected to offer a survival advantage over chemotherapy alone?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1801005">KEYNOTE-189</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key189_low.png">
        </div>
      </div>

      {% elif key189_risk == "Medium" %}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab plus chemotherapy expected to offer a survival advantage over chemotherapy alone?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1801005">KEYNOTE-189</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key189_med.png">
        </div>
      </div>
       
      {% elif key189_risk == "High"%}
      <p><span class="risk-benefit">Based on the patient's risk, is pembrolizumab plus chemotherapy expected to offer a survival advantage over chemotherapy alone?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://www.nejm.org/doi/full/10.1056/nejmoa1801005">KEYNOTE-189</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/key189_high.png">
        </div>
      </div>
      {% endif %}

      <div class="collapsible">
        <button class="collapsible-button">RCT comparison</button>
        <div class="content">
          <img src="../../static/images/lung/key189_summary.png">
        </div>
      </div>
    </div>
 
    <div class="space-result"></div>
 
    <!-- ZERO OR UNKNOWN PDL1: CHECKMATE-078 -->
    <div class="section-box">
      <p class="treatment"> Second-line nivolumab or docetaxel </p>

      <p><span class="risk-benefit">The patient's risk group when compared to others in routine practice who received one of the above therapies is:</span> {{ check_risk }} </p>

      {% if check_risk == "Low" %}
      <p><span class="risk-benefit">Based on the patient's risk, is second-line nivolumab expected to offer a survival advantage over docetaxel?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://pubmed.ncbi.nlm.nih.gov/30659987/">CHECKMATE-078</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/check_low.png">
        </div>
      </div>

      {% elif check_risk == "Medium" %}
      <p><span class="risk-benefit">Based on the patient's risk, is second-line nivolumab expected to offer a survival advantage over docetaxel?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://pubmed.ncbi.nlm.nih.gov/30659987/">CHECKMATE-078</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/check_med.png">
        </div>
      </div>
       
      {% elif check_risk == "High"%}
      <p><span class="risk-benefit">Based on the patient's risk, is second-line nivolumab expected to offer a survival advantage over docetaxel?</span> Yes</p>

      <p>Click below for more information on overall survival (OS) estimate in routine practice and how it compares to patients in <a href = "https://pubmed.ncbi.nlm.nih.gov/30659987/">CHECKMATE-078</a> trial:</p>
      <div class="collapsible">
        <button class="collapsible-button">OS estimate</button>
        <div class="content">
          <img src="../../static/images/lung/check_high.png">
        </div>
      </div>
      {% endif %}

      <div class="collapsible">
        <button class="collapsible-button">RCT comparison</button>
        <div class="content">
          <img src="../../static/images/lung/check_summary.png">
        </div>
      </div>
    </div>
    {% endif %}

    <!-- ALK POSITIVE -->
    {% if bio_status == 'alk_positive' %}
    <div class="section-box">
      <p class="empty">No survival estimates available for ALK inhibitors.</p>
    </div>
    {% endif %}

    <div class="space-result"></div>
    <button class="back-button" onclick="window.location.href='/lung'">Back to form</button>
    <button class="home-button" onclick="window.location.href='/'">Home</button>
    <script src="../../static/scripts/myscripts.js"></script>
  
  </body>
</html>
      

